This is from a 2014 article in medicalxpress.  Don't believe we had it posted before -- can't see it in the Link Library, so apologies if we've talked about it before.

Jonas Nilsson of the Sahlgrenska Cancer Center at the University of Gothenburg is featured and talks about working with Zenith on what, at the time, was RVX2135.  Not sure if this was the old molecule that was passed on due to some patent controversies or if it is now ZEN3694. 

https://medicalxpress.com/news/2014-06-combination-treatment-cancer.html

Anyways, it's encouraging to find Zenith being mentioned in various publications (even when our management team doesn't "toot the horn" enough to let the rest of the world know about it).

masila